Study guide

12.1 Diabetes Mellitus, Hypoglycemia & Metabolic Emergencies

USMLE Step 2 CK Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Human Development & Well-Patient Care

1.1 Infant, Child & Adolescent Development & Growth 1.2 Adult Development, Aging & Geriatric Assessment 1.3 Preventive Health, Immunization & Well-Patient Screening

2 Chapter 2: Immune System & Immunologic Disorders

2.1 Primary & Secondary Immunodeficiencies 2.2 Hypersensitivity Reactions, Allergy & Anaphylaxis 2.3 Autoimmune & Rheumatologic Disease Principles

3 Chapter 3: Blood & Lymphoreticular System

3.1 Anemias: Microcytic, Normocytic & Macrocytic Etiologies 3.2 Bleeding Disorders, Coagulopathies & Platelet Pathology 3.3 Hematologic Malignancies & Lymphoproliferative Disorders

4 Chapter 4: Behavioral Health & Psychiatric Disorders

4.1 Mood Disorders: Major Depression & Bipolar Spectrum 4.2 Anxiety, Trauma-Related & Somatic Symptom Disorders 4.3 Psychotic Disorders & Schizophrenia Spectrum 4.4 Substance Use Disorders & Psychopharmacology

5 Chapter 5: Nervous System & Special Senses

5.1 Cerebrovascular Disease, Stroke & Transients 5.2 Seizures, Epilepsy & Altered Mental Status 5.3 Movement Disorders, Dementia & Peripheral Neuropathies 5.4 Special Senses: Ophthalmologic & Otolaryngologic Emergencies

6 Chapter 6: Musculoskeletal System & Dermatology

6.1 Fractures, Dislocations & Orthopedic Trauma 6.2 Inflammatory Arthropathies & Crystal-Induced Diseases 6.3 Inflammatory & Infectious Dermatoses 6.4 Cutaneous Malignancies & Blistering Disorders

7 Chapter 7: Cardiovascular System

7.1 Coronary Artery Disease & Acute Coronary Syndromes 7.2 Heart Failure, Cardiomyopathies & Valvular Disease 7.3 Cardiac Arrhythmias, Conduction Blocks & EKG Interpretation 7.4 Vascular Emergencies: Aortic Aneurysms & Peripheral Arterial Disease

8 Chapter 8: Respiratory System

8.1 Obstructive Airway Diseases: Asthma & COPD 8.2 Infectious Pneumonias & Pleural Effusions 8.3 Pulmonary Vascular Disease & Thromboembolism 8.4 Acute Respiratory Distress Syndrome & Interstitial Lung Diseases

9 Chapter 9: Gastrointestinal System

9.1 Esophageal, Gastric & Peptic Ulcer Disorders 9.2 Inflammatory Bowel Disease & Colorectal Neoplasms 9.3 Hepatic Disorders, Cirrhosis & Portal Hypertension 9.4 Biliary Tract Diseases & Pancreatitis

10 Chapter 10: Renal, Urinary & Reproductive Systems

10.1 Acute Kidney Injury & Chronic Kidney Disease 10.2 Glomerular & Tubulointerstitial Diseases 10.3 Nephrolithiasis, Urinary Tract Infections & Prostate Pathology 10.4 Fluid, Electrolyte & Acid-Base Disorders 10.5 Female Reproductive Disorders & Gynecology 10.6 Breast Pathology & Clinical Breast Disease

11 Chapter 11: Pregnancy, Childbirth & Puerperium

11.1 Normal Prenatal Care & Maternal-Fetal Physiology 11.2 Medical & Obstetric Complications of Pregnancy 11.3 Labor, Delivery & Postpartum Management

12 Chapter 12: Endocrine System

12.1 Diabetes Mellitus, Hypoglycemia & Metabolic Emergencies 12.2 Thyroid & Parathyroid Disorders 12.3 Adrenal & Pituitary Axis Pathology

13 Chapter 13: Multisystem Processes & Critical Care

13.1 Shock States, Sepsis & Systemic Inflammatory Response 13.2 Environmental Emergencies, Toxicology & Overdose 13.3 Infectious Disease Principles & Systemic Pathogens

14 Chapter 14: Biostatistics, Epidemiology & Literature Interpretation

14.1 Study Designs, Bias & Validity 14.2 Diagnostic Testing: Sensitivity, Specificity, PPV & NPV 14.3 Statistical Significance, Risk Measures & Evidence-Based Medicine

15 Chapter 15: Social Sciences, Ethics & Systems-Based Practice

15.1 Medical Ethics, Informed Consent & Patient Autonomy 15.2 Legal Issues, Confidentiality & Surrogate Decision Making 15.3 Patient Safety, Quality Improvement & Medical Error Analysis 15.4 Health Care Delivery Systems, Interprofessional Care & Transitions

12.1 Diabetes Mellitus, Hypoglycemia & Metabolic Emergencies

Key Takeaways Explain This Topic AI

Diabetes mellitus is diagnosed by fasting plasma glucose ≥126 mg/dL, 2-hour 75g OGTT ≥200 mg/dL, HbA1c ≥6.5%, or random plasma glucose ≥200 mg/dL with classic hyperglycemic symptoms.

First-line T2DM pharmacotherapy is metformin (contraindicated if eGFR <30 mL/min/1.73m²); SGLT2 inhibitors and GLP-1 receptor agonists provide proven organ protection in CKD, heart failure, or ASCVD.

Diabetic Ketoacidosis (DKA) features blood glucose ≥200 mg/dL or known diabetes (about 10% are euglycemic), elevated ketones, and pH <7.30 and/or serum bicarbonate <18 mEq/L, usually with an anion gap >12 mEq/L (2024 adult consensus), whereas HHS presents with blood glucose >600 mg/dL without marked ketoacidosis.

In DKA and HHS management, insulin must be withheld if serum potassium is <3.5 mEq/L until potassium is repleted, and IV 5–10% dextrose is added when blood glucose drops below 250 mg/dL (DKA) or to ≤300 mg/dL (HHS).

Whipple's triad establishes a diagnosis of hypoglycemia: neuroglycopenic/autonomic symptoms, blood glucose <55 mg/dL, and prompt symptom resolution with glucose administration.

Last updated: October 2026

  • Diabetes Mellitus, Hypoglycemia & Metabolic Emergencies
  • Diagnostic Standards and Screening Algorithms for Diabetes Mellitus

Diabetes mellitus comprises a heterogenous group of metabolic disorders characterized by persistent hyperglycemia resulting from defects in insulin secretion, insulin action, or both. The American Diabetes Association (ADA) establishes strict, standardized laboratory thresholds for diagnosing diabetes mellitus and prediabetes.

Diagnostic Criteria for Diabetes Mellitus and Prediabetes

Screening should be initiated in all asymptomatic adults aged 35 years or older, or in adults of any age with an elevated Body Mass Index (BMI ≥25 kg/m², or ≥23 kg/m² in Asian Americans) who possess one or more additional risk factors (e.g., first-degree relative with diabetes, hypertension, physical inactivity, dyslipidemia). In the absence of unequivocal symptomatic hyperglycemia (e.g., polyuria, polydipsia, unexplained weight loss), a diagnosis requires two abnormal test results from the same sample or two separate test samples.

Diagnostic Category Fasting Plasma Glucose (FPG) 2-Hour 75-g OGTT Glycated Hemoglobin (HbA1c) Random Plasma Glucose

  • Normal <100 mg/dL (5.6 mmol/L) <140 mg/dL (7.8 mmol/L) <5.7% (39 mmol/mol) N/A
  • Prediabetes 100–125 mg/dL (5.6–6.9 mmol/L) 140–199 mg/dL (7.8–11.0 mmol/L) 5.7–6.4% (39–47 mmol/mol) N/A

Diabetes Mellitus ≥126 mg/dL (7.0 mmol/L) ≥200 mg/dL (11.1 mmol/L) ≥6.5% (48 mmol/mol) ≥200 mg/dL + Symptoms [ Suspected Diabetes Mellitus ]

  • │
  • ┌───────────────────────────────┴───────────────────────────────┐
  • [ Random Glucose ≥200 mg/dL + ] [ Asymptomatic Patient ]
  • [ Classic Symptoms (Polyuria) ] │
  • │ ┌────────────────┴────────────────┐
  • ▼ [ Order FPG, HbA1c, or OGTT ] [ HbA1c <5.7% / FPG <100 ]
  • DIABETES CONFIRMED │ │
  • ┌──────────────┴──────────────┐ ▼
  • [ Single Test Positive ] [ Two Tests Positive ] NORMAL (Re-screen 3 yr)
  • │ │
  • ▼ ▼
  • [ Repeat Same or 2nd ] DIABETES CONFIRMED
  • [ Test on New Sample ]
  • │
  • ┌───────┴───────┐
  • [ Positive ] [ Negative ]
  • │ │
  • ▼ ▼
  • DIABETES RE-EVALUATE
  • Pharmacotherapeutic Management of Type 2 Diabetes Mellitus

The primary therapeutic objective in managing type 2 diabetes mellitus (T2DM) is achieving individualized glycemic control to prevent microvascular (retinopathy, nephropathy, neuropathy) and macrovascular complications. The general HbA1c target for non-pregnant adults is <7.0% (53 mmol/mol) . However, a more stringent target of <6.5% is appropriate for younger patients with short disease duration and minimal hypoglycemia risk, whereas a relaxed target of <8.0% is indicated for patients with limited life expectancy, severe hypoglycemia history, or extensive comorbid conditions.

First-Line Therapy and Comorbidity-Driven Escalation

Metformin : Biguanide that decreases hepatic gluconeogenesis and increases peripheral insulin sensitivity. Metformin does not cause hypoglycemia or weight gain. Common side effects are gastrointestinal distress (nausea, diarrhea). It is contraindicated when eGFR is <30 mL/min/1.73m² due to the risk of lactic acidosis . Dose reduction is recommended if eGFR falls between 30 and 45 mL/min/1.73m².

SGLT2 Inhibitors (Empagliflozin, Dapagliflozin, Canagliflozin) : Inhibit sodium-glucose cotransporter 2 in the renal proximal convoluted tubule, promoting glucosuria. They are indicated independently of baseline HbA1c in patients with heart failure (HFrEF/HFpEF) , chronic kidney disease (eGFR ≥20–25 mL/min/1.73m² with albuminuria) , or established Atherosclerotic Cardiovascular Disease (ASCVD) . Adverse effects include mycotic genital infections, urinary tract infections, volume depletion/hypotension, and euglycemic DKA .

GLP-1 Receptor Agonists (Semaglutide, Liraglutide, Dulaglutide) : Incretin mimetics that enhance glucose-dependent insulin secretion, suppress glucagon release, and delay gastric emptying. Preferred in patients with established ASCVD , indicators of high cardiovascular risk, or where weight loss is a primary goal. Adverse effects include nausea, vomiting, diarrhea, and a risk of acute pancreatitis. They are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2 .

DPP-4 Inhibitors (Sitagliptin, Linagliptin) : Prevent degradation of endogenous incretins. Weight-neutral with low hypoglycemia risk, but saxagliptin and alogliptin carry a warning for increased heart failure hospitalization risk.

Sulfonylureas (Glipizide, Glimepiride, Glyburide) : Stimulate pancreatic beta-cell insulin secretion by closing ATP-sensitive potassium channels. Associated with weight gain and significant hypoglycemia risk . Glyburide has active renal metabolites and should be avoided in renal impairment.

Insulin Regimens : Initiated when HbA1c is severely elevated (>10% or blood glucose ≥300 mg/dL) or when oral agents fail. Basal insulin (glargine, degludec) provides 24-hour coverage, supplemented by prandial rapid-acting insulin (lispro, aspart) before meals.

Hyperglycemic Emergencies: DKA vs. HHS

Diabetic Ketoacidosis (DKA) and Hyperosmolar Hyperglycemic State (HHS) represent catastrophic, life-threatening metabolic crises resulting from insulin deficiency and counter-regulatory hormone excess (glucagon, cortisol, catecholamines, growth hormone).

Clinical Characteristic Diabetic Ketoacidosis (DKA) Hyperosmolar Hyperglycemic State (HHS)

Primary Patient Population Type 1 Diabetes Mellitus (can occur in T2DM) Type 2 Diabetes Mellitus (elderly, nursing home)

Plasma Glucose ≥200 mg/dL or known diabetes (euglycemic DKA <200 in about 10%) >600 mg/dL (frequently >1000 mg/dL)

  • Arterial pH <7.30 (Severe DKA: <7.00) >7.30
  • Serum Bicarbonate <18 mEq/L (Severe DKA: <10 mEq/L) >18 mEq/L
  • Anion Gap >12 mEq/L (High Anion Gap Acidosis) Normal or slightly elevated (<12 mEq/L)
  • Serum/Urine Ketones Strongly Positive (Beta-hydroxybutyrate) Absent or minimal
  • Effective Serum Osmolality Variable (<320 mOsm/kg) >320 mOsm/kg
  • Neurologic Status Alert to drowsy; Kussmaul breathing Severe lethargy, stupor, coma, focal deficits
  • Stepwise Protocol for DKA and HHS Management

Fluid Resuscitation : Infuse isotonic saline or a balanced crystalloid at 500–1,000 mL/hr for the first 2–4 hours (smaller 250 mL boluses in older adults, heart failure, or dialysis) to restore intravascular volume. Switch to 0.45% NS if corrected sodium is normal or high. When blood glucose drops below 250 mg/dL in DKA (or to ≤300 mg/dL in HHS ), add 5–10% Dextrose to IV fluids to allow continued IV insulin administration without triggering hypoglycemia or cerebral edema.

Potassium Replacement : Check serum potassium prior to insulin initiation.

If K⁺ <3.5 mEq/L: HOLD insulin . Administer IV KCl (about 10 mEq/hr) until K⁺ >3.5 mEq/L (2024 adult consensus).

If K⁺ 3.5–5.0 mEq/L: Administer IV KCl (20–30 mEq per liter of IV fluid) and initiate Regular Insulin drip.

If K⁺ >5.0 mEq/L: Do not add potassium yet; start Regular Insulin drip, recheck K⁺ 2 hours after insulin starts and then every 4 hours, and add potassium once it falls below 5.0.

Insulin Therapy : Continuous IV Regular Insulin drip at 0.1 units/kg/hr . Do not give a bolus if potassium is low. DKA is resolved when plasma ketone (beta-hydroxybutyrate) is <0.6 mmol/L AND venous pH is ≥7.3 or serum bicarbonate is ≥18 mEq/L; ideally, glucose is also <200 mg/dL. Do not use the anion gap or urine ketones to define resolution (2024 adult consensus).

Hypoglycemia & Endogenous Hyperinsulinism

Hypoglycemia is defined clinically by Whipple's triad : (1) symptoms consistent with hypoglycemia (autonomic: tremor, palpitations, diaphoresis; neuroglycopenic: confusion, seizures, altered mental status), (2) a documented low plasma glucose concentration ( <55 mg/dL in non-diabetics), and (3) prompt relief of symptoms following glucose administration.

Differential Diagnosis of Hyperinsulinemic Hypoglycemia

When evaluating an adult without diabetes presenting with spontaneous hypoglycemia, serum insulin, C-peptide, proinsulin, and beta-hydroxybutyrate must be measured during a symptomatic episode or 72-hour fast.

  • Parameter Insulinoma Exogenous Insulin Injection Surreptitious Sulfonylurea Use
  • Serum Insulin Elevated (>3 µIU/mL) Extremely Elevated Elevated (>3 µIU/mL)
  • Serum C-Peptide Elevated (≥0.6 ng/mL) Suppressed (<0.2 ng/mL) Elevated (≥0.6 ng/mL)
  • Proinsulin Elevated Normal or Low Elevated
  • Screen for Oral Hypoglycemics Negative Negative Positive (Urine/Serum)